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Abstract  
Background: Dopaminergic drugs are the primary risk factor for Impulse Control 
Behaviours (ICB) in Parkinson’s disease (PD), others being early-onset disease and gender. 
Objective: This report further explores ICB symptom relationships with motor and mood 
phenotypes, the complex relationship with dopaminergic medications, and hypothesizes a 
model with potential clinical implications.  
Methods: Data from 500 PD patients were analyzed. Hypersexuality, gambling and shopping 
behaviour were assessed using selected questions from the Minnesota Impulsive Disorders 
Interview questionnaire. Local questions assessed hobbyism. Motor characteristics 
considered were akinetic-rigid/gait disturbance (PIGD) and ‘non-PIGD’ phenotypes, motor 
severity, motor progression, and presence/absence of motor fluctuations. Other variables 
included anxiety, depression, current levodopa and agonist use, age, gender and cognition.    
Results: Overall, ICB symptom frequency was 17.8%. There was no relationship between 
PIGD/non-PIGD motor phenotypes and ICB symptoms. Those with ICB symptoms had 
higher total combined levodopa/agonist equivalent intake, but not current agonist-only 
equivalent intake. ICB symptoms were reported by 23.1% of those taking combined levodopa 
and agonist compared to 19.2% on agonist monotherapy and 11.6% levodopa monotherapy. 
Compared with non-ICB patients, patients with ICB symptoms were more likely to show an 
anxious mood phenotype, reported more motor fluctuations, and were younger.  
Conclusions:  Both PIGD and non-PIGD phenotypes are equally affected. Dose-related risk 
applies to total anti-parkinsonian medication and not just current agonist-only. Anxious mood 
phenotypes may carry increased risk. A role of anxiety, either as a marker of risk, indirect 
causal factor, or maintaining factor is incorporated into a preliminary model. We discuss 
implications for clinical management. 
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Introduction  
Impulse Control Behaviours (ICB), including pathological gambling, compulsive shopping, 
eating, and sexual behaviour are more common in treated Parkinson’s disease (PD) patients 
than in the general population, with prevalence rates of approximately 6-25% [1-3]. The 
association between PD and ICB may relate to the pathophysiology of PD, its treatment and 
their interactions, or other currently unidentified factors. Identifying ICB risk factors may 
enable better understanding of how ICB emerge and are maintained, and may provide new 
research avenues for management. 
Converging evidence supports the existence of distinct motor phenotypes in PD, particularly 
a postural instability/gait difficulty (PIGD) and tremor-dominant subtypes[4-7]. One aim of 
the present study was to determine if motor phenotypes, have a relationship to ICB symptoms 
and thereby offer clues to pathophysiology. Other motor characteristics were also studied. 
Second, we assessed the complex relationship between antiparkinsonian medication (agonists 
and levodopa) and ICB symptoms, specifically current dopamine-agonist-only, levodopa-
only, and total levodopa equivalent doses. Finally, we assessed whether specific mood 
phenotypes [8] had a relationship to ICB symptoms.  
 
Methods 
The PROMS-PD project is a prospective study of mood states in PD [8]. Briefly, participants 
were recruited consecutively from patients attending outpatient appointments at secondary 
neurology and care of the elderly clinics in 5 UK centres over a 12 month period. Diagnosis 
of idiopathic PD was based on the UK Brain Bank clinical diagnostic criteria [9]. Patients 
with other parkinsonian diagnoses, severe hearing or visual loss, severe communication 
difficulties or severe cognitive impairment and unable to give informed consent were 
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excluded. The study was approved by the South East NHS Research Ethics Committee, 
Ref:(07/MRE01/9). Information was collected from the patient and/or informant on clinical 
history, current treatment and socio-demographics. Motor symptoms were assessed at the 
time. Levodopa equivalent daily dose (LEDD) was calculated using conversion factors 
described previously [10]. 
 
Motor characteristics 
The Unified Parkinson’s Disease Rating Scale III (UPDRS) [11] and Hoehn and Yahr scale 
[4] were used to assess motor symptoms. Patients were examined in the on-state for practical 
reasons. Further, patients were classified as akinetic-rigid with gait disturbance (PIGD), 
tremor-dominant (TD), or no clear subtype as described previously [13] based on the 
classification proposed by Jankovic and colleagues [5]. We hypothesised that the PIGD 
phenotype, typically being more severe, requiring more aggressive medical therapy, [7,9,12]  
would have a higher prevalence of ICB symptoms. It was also hypothesised that patients with 
faster progression rates could potentially have greater and more frequent escalation in 
dopaminergic medication and therefore be at greater risk of ICB symptoms. An index of 
progression was obtained from the summed scores of UPDRS parts I-III divided by disease 
duration (years) as described previously [6, 13]. Participants were classified as ‘fast’ or 
‘slow’ progressers depending on whether their index was higher (fast) or lower (slow) than 
the group median (Table 3). An index of motor variability was assessed as those reporting 
unpredictable or sudden off (UPDRS IV)[13] . 
 
Affective and cognitive assessments 
Based on previously described psychiatric symptoms [8], participants’ mood was classed as 
depressed, anxious, anxious and depressed or ‘healthy’. The Hospital Anxiety and Depression 
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Scale (HADS), validated for use in PD[14], was also used to assess severity of depression 
and anxiety. A subscale score >10 indicates clinically significant depressive or anxiety 
symptoms. The Addenbrooke’s Cognitive Exam-Revised (ACE-R), validated for use in 
PD[15], was used to assess cognition, with a score of < 84 indicating cognitive impairment.  
 
ICB symptoms 
As part of a larger semi-structured psychiatric interview, ICB symptoms were assessed using 
questions from the Minnesota Impulsive Disorders Interview (MIDI) [16]. They were 
considered to have an ICB if they responded positively to one or more questions relating to 
sexual behaviour, gambling and shopping respectively. In addition, local screening questions 
were included concerning the presence of hobbies and other repetitive activities that took up 
large amounts of time and interfered with other activities including sleep (see appendix). The 
term Impulse Control Behaviour (ICB) symptoms will be used in this manuscript to describe 
symptoms of only sexual behaviour, gambling, shopping and hobbyism collectively, as a 
subset of known impulsive / compulsive states in PD. Other ICBs and related problems 
(including excessive eating, walkabout, punding, creativity, risk-taking behaviour or 
Dopamine Dysregulation Syndrome (DDS)) were not assessed as part of the PROMS-PD 
project and cannot be included in this manuscript.  
 
Statistical Analysis 
Descriptive statistics were used to explore the prevalence and type of ICB symptoms. 
Univariate tests (independent samples t-tests (normally distributed data) and Mann-Whitney 
U tests (non-normally distributed data)) were performed to explore relationships between 
ICB symptoms and the clinical and demographic variables. Chi-squared analysis was used to 
explore the relationships between gender, motor phenotype, motor symptoms, mood 
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phenotype and ICB symptoms. Mann-Whitney U tests were used to compare medication 
levels between ICB and non-ICB participants. Finally, a binary logistic regression analysis 
was performed to explore statistical predictors of ICB symptoms. Only variables showing 
significant relationships in the univariate analyses were entered into the model.  
 
Results 
Demographics 
In this study, 525 patients participated but 25 were excluded as they were not taking 
dopaminergic medication and did not demonstrate ICBs. Males numbered 326, females 174. 
The sample was 96.2% white British. Mean age was 67.9 years (SD 10.4), median disease 
duration was 7.1 years (Interquartile range 6.0) and mean “on” UPDRS III score was 26.8 
(SD12.0). At least one ICB symptom was identified in 17.8% of participants. Five percent 
reported two or more ICBs (Table 1).  
 
Men were statistically more likely than women to report compulsive gambling (Table 1), but 
no relationship was found between gender and presence of ICB symptoms overall (Table 1). 
Participants with ICB symptoms were younger by a mean of 5.7 years and had marginally 
better cognitive function (Table 2). 
 
Motor phenotypes 
Most patients were classified as PIGD (78.8%), 13.4% as TD, and 7.8% had no clear subtype. 
With the exception of slightly lower UPDRS-III scores in the TD participants, the two non-
PIGD subtypes did not differ in age, gender, anxiety, depression, cognition, disease duration, 
progression or motor fluctuations, suggesting similar clinical and demographic profiles. For 
this reason, they were combined into a ‘Non-PIGD’ group (21.2%). 
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No significant relationships were found between motor phenotypes, or rate of progression (as 
assessed by our index), and ICB symptoms (Table 3). ICB symptoms were however more 
common in patients with motor fluctuations. No significant associations were found between 
individual ICBs and motor phenotype (hobbyism = χ2=0.256, df=1, p=0.613, compulsive 
gambling = Fisher’s Exact Test p=0.546, compulsive shopping= χ2=0.399, df=1, p=0.527, 
hypersexuality = Fisher’s Exact Test p=0.331). Hobbyism (χ2=7.837, df=1, p=0.005) and 
compulsive shopping (χ2=7.112, df=1, p=0.008) were more common in patients with motor 
fluctuations.  
 
Medication 
The median current total LEDD in the ICB group was significantly higher than the non-ICB 
group. A significant difference was found for current agonists use, in that  by 74.2% of 
participants with ICB symptoms used current agonists, compared with 56.7% without ICBs 
(χ2=9.284, df=1, p=0.002). However, the median current agonist-only and levodopa-only 
LEDD did not differ significantly between groups (Table 3). Rates of ICB symptoms were 
higher in participants on combined levodopa/agonist therapy (23.1%) than those on 
monotherapy (agonist only 19.2%, levodopa only 11.6%) (χ2=9.915, df=3, p=0.019). 
 
Mood 
Patients with ICB symptoms had significantly higher HADS anxiety scores than those 
without ICB (Table 2) but not depression scores. Chi-squared tests (Table 3) identified a clear 
relationship between the presence of ICB symptoms and both anxiety-related phenotypes 
(anxious alone phenotype, and anxious/depressed phenotypes) relative to the ‘Healthy’ group, 
but no association with the phenotype characterised by depression without anxiety. This 
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pattern was also seen in the relationships between individual ICBs and mood phenotypes. 
Hobbyism was more common in the anxious/depressed (34%) and anxious (22%) groups than 
the depressed (10%) and healthy groups (8%) (χ2=16.914, df=3, p=0.001). Gambling was 
more common in the anxious/depressed group (13%) than the depressed (2%), anxious (4%) 
and healthy (2%) groups (χ2=9.765, df=3, p=0.021). Shopping was more common in the 
anxious/depressed (13%) and anxious groups (13%) than the depressed (2%) and healthy 
(4%) groups (χ2=12.470, df=3, p=0.006). 
 
Predictors of ICB 
Variables significantly associated with ICB symptoms were entered into a binary logistic 
regression model (Table 4), initially individually (unadjusted odds ratio) and then combined 
(adjusted odds ratio). All variables, with the exception of depressed mood phenotype, 
significantly predicted ICB in the unadjusted models. In the combined adjusted model, only 
two significant predictors were identified: mood phenotype and age. Medication related 
variables did not contribute significantly to the adjusted model. The model suggests that 
younger participants and those with an anxious or anxious/depressed mood phenotype were 
more likely to experience ICB. The final model correctly classified 82.5% of cases as ICB 
symptoms or non-ICB although this is biased by the high prevalence of non-ICB cases. 
 
Discussion and hypothesis 
This large cohort study investigated relationships of ICB symptoms with clinical 
characteristics. Although smaller than the study of Weintraub [1] and assessing a narrower set 
of ICB and related problems, we explored a broad range of features, including motor, 
medication and affective phenotypes. The demographics, prevalence data and ICB 
characteristics were comparable with previous studies, e.g.[1], suggesting that our cohort was 
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similar to previously published cohorts, and is a clinically representative sample. Our data are 
largely confirmatory and we use them to develop a hypothesis with potential clinical and 
research implications. 
 
Motor phenotypes 
Data on the relationships between motor phenotypes and impulsivity to date are conflicting. 
Two recent studies suggest that akinetic-rigid patients may have more susceptibility to ICB 
[17, 18]. In contrast, our data, and those of Voon et al [19], suggest a similar prevalence of 
ICB symptoms among different PD motor subtypes. These variations are potentially 
explained by differences in impulsivity measures (reaction time studies vs. ICB screening 
tools). We suggest that both PIDG and non-PIGD motor phenotypes require similar 
surveillance for development of these behaviours.  
 
Further exploration showed no clear relationships between rate of progression (as assessed by 
the methods in this study) and ICB symptoms. It has been reported previously that young-
onset PD patients typically develop motor fluctuations and dyskinesias earlier [20]. Our data 
showed that younger patients and those with motor variability reported more ICB symptoms. 
These findings could be explained if young-onset disease and fluctuating (motor or non-
motor) disease share a distinct pathological mechanism, but pathological evidence is 
currently lacking. Alternatively these associations may simply reflect that younger patients 
with fluctuations are more likely to take more medication to combat this, and consequently 
develop more drug-induced ICB. One important aim of future research will be the 
examination of associations of ICB and/or motor and non-motor fluctuations and the bearing 
that is imposed on these by pulsatile versus continuous delivery of treatment (whether by 
subcutaneous or intrajejunal dopaminergic therapy or by continuous high frequency deep 
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brain stimulation). Evidence of these effects is currently lacking but recent publications are 
beginning to explore this concept [21]. If such associations are confirmed, then these could 
lead to better identification of susceptible patients and to potential choice of therapy.  
 
Medication 
The relationship of medication with ICB is complex because of the large number of 
medications available to treat motor symptoms in PD over time. The discussion and 
hypotheses in this manuscript are confined to agonists and levodopa, as these have been the 
focus of the majority of previously published reports. Our results add to this field by 
supporting the positive association between ICB symptoms and treatment with agonists 
(proposed as a class effect) and levodopa [1]. More patients with ICBs were taking agonists 
and although the current median dose of agonist-only LEDD was higher in the ICB group, 
this difference did not reach statistical significance even in this large sample, suggesting the 
absence of a substantial dose-dependent effect, similar to previous conclusions [1,19]. 
However, from the general clinical experience, some ICBs can sometimes improve by dose 
reduction and evidence of a dose-related agonist association has been described in two recent 
ICD studies [22,23].  One explanation for these differences could be considerable individual 
differences in dose thresholds for the appearance of ICB. The identification of which PD 
patients would be susceptible to the development of ICBs, and, if possible the identification 
of a threshold dose, could have clinical implications in directing treatment. For example, for 
an analogous clinical scenario, one can consider the management of patients who have 
suffered transient ischaemic attacks (identified as susceptible individuals) being offered 
stroke prophylaxis (an appropriate dose of drug depending on the risk factor for the transient 
ischaemic attack). 
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The relationship of ICB symptoms with levodopa is also complex, and therefore in this 
manuscript, we additionally explore the role that levodopa may have in ICB symptoms 
because Levodopa’s role has received less recent attention than agonists. The recent study 
[23] did not report a relationship with levodopa use and a recent review reported that 
levodopa monotherapy is not associated with pathological gambling [24]. In contrast, and in 
line with the largest study [1], we found that a higher total LEDD was related to ICB 
symptoms. Further, and perhaps related to this, ICB symptoms were present in more patients 
taking combined levodopa and agonist than agonist alone. Almost 12% of patients in the non-
agonist group developed ICB symptoms, similar to previous reports [1] and confirming the 
need to raise awareness of the role of levodopa in ICB. Voon et al.[19] extend this concept 
further by showing differential levodopa doses with ICB subtypes. In that study patients with 
ICBs (single or multiple) were receiving more levodopa when compared with those without 
ICBs, but the highest levodopa doses were seen in patients with compulsive shopping and 
sexual behaviour, in contrast to those with problem / pathological gambling and binge eating.  
From these large studies, three considerations can be contemplated for risk management and 
communication: (i) patients on levodopa monotherapy can develop ICB symptoms and 
therefore also require counseling, (ii) some patients on agonists may be at risk even at low 
dose of the agonist, (iii) patients on combined levodopa and agonist seem to have the highest 
frequency of ICB symptoms, particularly as total LEDD increases. Patients with early PD 
often are managed on a single drug (whether agonist or levodopa alone) early in the disease. 
These results suggest that the risks of development of ICB symptoms might increase further 
at the time of increasing overall medication intake by the addition of the second agent. We do 
not know if this finding is dependent on which class of drug is offered first, or is uniform 
across all ICB, but it suggests that additional counseling should be offered to patients at the 
time of starting combined pre-synaptic and postsynaptic dopaminergic medications. Other 
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medication factors require future detailed exploration, including assessing the combined use 
of agonist and levodopa in different proportions but with constant total LEDD, the nature of 
delivery (pulsatile or continuous), or introduction of a third or fourth class of 
antiparkinsonian medication eg COMT inhibitors or MAO inhibitors and the controversy 
over the use of amantadine [25]. 
 
Mood phenotype 
Patients with anxiety were more likely to experience an ICB symptom than psychologically 
healthy or depressed patients, consistent with previous findings of increased state and trait 
anxiety in ICD [19]. We have previously reported that anxiety-related phenotypes are 
associated with younger onset-disease [8], potentially suggesting that they share common risk 
factors. Furthermore, the anxious phenotypes were associated with motor fluctuations [13] 
possibly describing a broad clinical phenotype of motor and neuropsychiatric features 
associated with young-onset disease. In PD, anxiety influences quality of life [26] but the 
mechanism by which anxiety may influence expression of other parkinsonian symptoms, 
including ICB, requires exploration. Appreciation of these mechanisms is important to aid 
understanding of the evolution and maintenance of the problem behaviours. For hypothesis 
generation and future research, we suggest a preliminary model that draws together the main 
factors considered in this study. The model (Figure 1) does not seek to be comprehensive and 
the directions of causality are speculative, but should be testable with new research. 
 
PD pathophysiology and dopaminergic stimulation remain central in the proposed model. 
ICB symptoms may arise from, or could be maintained by, a combination of direct and 
indirect factors related to the individual, the disease or treatment. Young-onset disease, 
perhaps because of distinctive pathophysiology or the nature and duration of treatment, may 
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contribute to higher medication levels. Higher medication levels are associated clinically with 
motor fluctuations. Other trait factors, such as harm avoidance (high in PD)[27] predating the 
onset of PD may prompt patients to seek more medication due to perceived under-treatment, 
while those patients (particularly younger) high in reward dependence trait[28] may be 
seeking a stimulant-like response. In anxiety-prone patients, unpredictable non-motor 
fluctuation may increase anticipatory anxiety, exacerbate anxiety or dysphoria during off-
periods [29]. A recent qualitative study suggested that for some patients ICB is used as a 
strategy helping them cope with a chronic uncontrollable condition [30]. While ICB 
symptoms may offer a short-term coping response (e.g. distraction), the longer-term negative 
consequence may feed the mood problem in a vicious cycle, maintaining the behaviour. 
Where this anxiety or the ICB drives a request for escalation of medication, the problems are 
exacerbated further. The model of anxiety as a direct or indirect influence on ICB symptoms 
suggests new avenues for research and treatment for ICB. Indeed, a recent randomized trial of 
Cognitive Behaviour Therapy for the management of ICB symptoms showed a positive 
outcome [31] and included targeted treatment of anxiety as part of the treatment protocol.  
 
Limitations of our results and hypotheses require mention. The logistic regression model 
identified only two significant predictors of ICB symptoms: mood phenotype and age. 
Interestingly the effect of mood was much stronger than that of medication, suggesting that in 
this cohort, ICB are not simply a consequence of dopaminergic medication. However, only 
82.5% of the cases were correctly classified as ICB/Non-ICB and this figure will be inflated 
by the high proportion of non-ICB patients, suggesting that other factors not assessed in this 
study play a role in determining whether patients develop ICB. Additionally, patients were 
recruited through hospital clinics. Consequently the prevalence rates may not fully translate 
to patients managed in the community, who may have fewer motor or non-motor 
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complications. We assessed only a limited subset of ICB symptoms, determined through the 
use of the MIDI questionnaire rather than through a structured clinical interview or formal 
diagnostic criteria, while hobbyism was assessed using local questions which captured the 
presence of ICB, but not the severity. However the aim was to detect symptoms and 
formulate hypotheses, rather than diagnose ICB. Threshold symptoms suggest increased risk 
of more serious ICB in the future[29], consequently the inclusion of these symptoms may 
provide important risk factor information. Other problems associated with ICB, such as DDS, 
and punding, were not assessed. A recent conceptual paper [29] proposed that ICB such as 
gambling, hypersexuality, eating and shopping are best classified as ‘behavioural addictions’ 
whilst other ICBs including punding, hoarding, walkabout and DDS represent qualitatively 
different behaviours with potentially different causal mechanisms. Further, for the present 
manuscript, we have combined the different behaviours under one umbrella term (ICBs) for 
hypothesis testing, and the present manuscript has not separated the different types of ICBs 
into classes. Different ICBs seem to have different associations with medications (eg 
gambling, sexuality, eating and shopping more with agonists, while punding / hobbyism  
more with levodopa), although overlap is not excluded. The subclassification of ICBs into 
groups is not without difficulty in interpretation as even within the same subtype of ICBs, 
some may have differing associations with medications [19] as shown previously. Currently, 
the best level of subclassification remains to be agreed uniformly. We did not address 
comprehensively previous (or peak) doses of medications which may have been reduced at 
the time of this study, thus reducing the reliability of our prevalence rates and associations 
with medications. Previous drug reduction themselves may have contributed to anxiety 
symptoms. Previous history of ICBs and family history of ICB, or substance abuse, 
psychiatric disturbances were not included. Lastly, at present there is no gold-standard 
definition of progression in PD and the index used provides only an estimate. Despite these 
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limitations, the present manuscript has generated hypotheses for future potential clinical 
testing. 
 
In conclusion, motor phenotype was not associated with ICB symptoms. Motor fluctuations 
when analyzed independently were significant associations. Dopamine agonist use was 
associated with higher ICB risk, but as previously suggested this relationship did not appear 
to be dose-dependent. More complex medication effects, including total dose and interactions 
with levodopa, may further enhance ICB manifestation. A role of anxiety, either as a marker 
of risk, indirect causal factor or maintaining factor is suggested, and may be a modifiable 
factor, and therefore a target for therapy. Identification of those at greater risk, however, does 
not imply no risk to those in low risk groups. Pre-treatment counseling and post-treatment 
surveillance should be available to all patients. The identification of clearer risk factors 
would, however, allow enhanced pre-treatment counseling for some. This could include the 
advantages/disadvantages of other forms of therapy, which have either more long-term motor 
side-effects (e.g. levodopa), or the acceptance by the patient to maintain less anti-
parkinsonian medication in general. Secondly, it would encourage both physicians and 
patients to accept frequent post-treatment surveillance.  
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Table 1. ICB symptom prevalence and association with gender 
 
 Point prevalence 
N, (%) 
Gender – % male  p value 
No ICB 411 (82.2) 63.7 - 
Any ICB 89 (17.8) 71.9           (p = 0.143) 
Gambling 17(3.4) 88.2 
 (p = 0.042) 
Shopping 30 (6.0) 66.7  (p = 0.855) 
Hypersexuality 15 (3.0) 86.7  (p = 0.076) 
Hobbyism 59 (11.8) 67.8  (p = 0.656) 
ICB = impulse control behaviour 
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Table 2. Clinical and demographic features of patients with and without ICB symptoms. 
 No ICB ICB p value 
  Range Mean (SD) Range Mean (SD)  
Age 39-94 68.9 (9.9) 32-85 63.2 (11.2) p < 0.001 
PD duration (years) 0-39 5.0 (8) † 0-25 6.0 (8)† p = 0.464 
Hoehn & Yahr 0-5 2.4 (0.9) 1-5 2.4 (0.8) p = 0.952 
UPDRS III  4-78 27.1 (12) 5-53 25.0 (11.9) p = 0.130 
HADS Anxiety Score 0-20 6.9 (4.4) 0-17 8.5 (4.3) p = 0.004 
HADS Depression Score 0-17 6.2 (3.6) 1-17 6.7 (3.9) p = 0.315 
ACE-R score 46-100 89.0 (14) † 53-100 91.0 (9.75)† p = 0.003 
†Median and  interquartile range 
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Table 3. Motor, medication and mood characteristics of patients with and without ICB 
symptoms 
Characteristic No ICB  
 
ICB  
 
Chi-squared statistic/ Mann-
Whitney U statistic (p value) 
Motor phenotypes N (%)† N (%)††  
PIGD 323 (78.6) 71 (79.8)  
Non-PIGD 88 (21.4) 18 (20.2)  χ2=0.06, df=1 (p=0.804) 
Total 411 89  
 
Rate of progression N (%)† N (%)††  
Slow 203 (49.4) 51(57.3)  
Fast 206 (50.1) 38 (42.3) χ2=1.72, df=1 (p=0.190) 
Total 409 89  
Missing**** 2 (0.5) 0 (0)  
 
Fluctuations N (%)† N (%)††  
No 303 (73.7) 54 (60.7)  
Yes 108 (26.3) 35 (39.3) χ2=6.10, df=1 (p=0.014) 
Total 411 89  
 
Medication Median (IR) 
(Range) 
Median (IR) 
(Range) 
 
Total current LEDD  
(N=500) 
730.0 (695) 
(37.5-3641.0) 
880.0 (795) 
(100.0-7565.0) 
U=21267.50 (p = 0.016) 
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Agonist-only 
current LEDD 
(N=299) 
300.0 (240) 
(25.0-2500.0) 
330.0 (285) 
(60.0-6340.0) 
U=8681.50 (p = 0.108) 
Levodopa-only 
current LEDD 
(N=410) 
510.0 (480) 
(50.0-2340.0) 
520.0 (415) 
(70.0-2660.0) 
U=13225.00 (p=0.313) 
 
Mood phenotypes N (%)† N (%)††  
Healthy* 259 (63.0) 35 (39.3) - 
Anxious 77 (18.7) 33 (37.1) χ2=18.72, df=1 (p0.001) 
Anxious/depressed 29 (7.1) 14 (15.7) χ2=12.88, df=1 (p0.001) 
Depressed 38 (9.2) 6 (6.7) χ2=0.11, df=1 (p=0.743) 
Total** 403 88  
Missing*** 8 (1.9) 1 (1.1)  
*Healthy group: patients with no affective symptoms. **Total number of patients who have 
full data. ***Missing participants who did not have full data=9 patients, therefore could not be 
classified by mood phenotype. **** Missing participants who did not have full data=2 patients, 
therefore could not be classified by progression.  
†
 % refers to the percentage of patients in each group as a proportion of the total sample 
without ICB symptoms (N=411) 
††
 % refers to the percentage of patients in each group as a proportion of the total sample with 
ICB symptoms (N=89). IR Interquartile Range
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Table 4: Logistic Regression Model of Predictors of ICB symptoms 
*Significant at P<0.05 
**Significant at P<0.01 
 
  
 
Unadjusted Odds 
Ratio (p) 
CI 
Adjusted Odds Ratio 
(p) 
CI 
     
Age (years) 0.95 (<0.001)** 0.93-0.97 0.97 (0.022)* 0.94-1.00 
ACE-R 1.04 (0.005)** 1.01-1.07 1.02 (0.136) 0.99-1.05 
Fluctuations 1.82 (0.014)* 1.13-2.94 1.00 (0.995) 0.57-1.74 
Total LEDD (mg) 1.06 (0.004)** 1.02-1.10 1.03 (0.234) 0.98-1.07 
Taking an agonist 2.19 (0.003)** 1.31-3.66 1.28 (0.549) 0.57-2.85 
Taking an agonist and 
levodopa 
1.90 (0.007)** 1.20-3.03 1.14 (0.745) 0.52-2.50 
Anxious vs healthy 3.17 (0.001)** 1.85-5.44 2.41 (0.003)** 1.36-4.26 
Anxious/depressed vs 
healthy 
3.57 (0.001)** 1.72-7.41 2.70 (0.017)* 1.20-6.08 
Depressed vs healthy 1.17 (0.743) 0.46-2.96 1.38 (0.516) 0.52-3.65 
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Figure 1 
Hypothetical model of compound factors contributing to the onset and/or maintenance of 
ICBs in PD  
 
 
 
 
 
Arrows indicate suggested unidirectional or bi-directional causality, dashed line indicate 
association without clear causation. Numbers refer to references supporting associations. 
DAWS = Dopamine Agonist Withdrawal Syndrome. 
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Appendix 
Hobbyism Questions 
1. Do you have any hobbies or pastimes? What sort of interests do you have? 
2. How often do you spend time on (hobby)?: Daily (7 days per week)/4-6 days per week/2-3 days per 
week/1 day per week or less frequent 
3. On these days how many hours would you spend doing the hobby? : <1 hour, 1-3 hours, 4-6 hours, 
≥7 hours 
4. Do you sometimes spend excessive amounts of time doing (hobby)? : No/Yes  
5. Do you find (hobby) calming, or brings you relief from feeling of tension? : No/Yes  
6. Has doing (hobby) interfered with your sleep at all in the past month – for example you have gone 
to bed later than usual because of it? No/Yes 
7. In the past month have you missed a whole night’s sleep doing (Hobby)? : No/Yes  
8. Do you feel that (hobby) sometimes interferes with other aspects of your life or daily routine? Does 
it stop you doing other things that you want to do? : No/Yes  
Patients responding positively to questions 6, 7 or 8 were classified as reporting excessive 
hobbyism. 
 
MIDI Questions 
 
1. Do you, or others that you know, think that you have a problem with being overly 
preoccupied with sex? (if ‘yes’, ask - ) for how long?: No/yes/ns 
2. Do you or others think that you have ever had a problem with gambling?: No/yes/ns 
3. Do you or others think that you have a problem with buying things too often or with spending 
too much money?: No/yes/ns 
 
Patient classified as having an ICB symptom if answering ‘yes’ to any question 
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